Shares of CSPC PHARMA (01093) climbed more than 12% following its interim results announcement, trading up 11.97% at HK$9.725 with turnover reaching HK$3.057 billion as of press time.

On August 20 at midday, the company released its 2026 interim results, showing total revenue of RMB 18.594 billion, a year-on-year increase of 40.1%, while profit attributable to shareholders surged 139.2% to RMB 6.094 billion, with basic earnings per share at RMB 0.5345. An interim dividend of HK$0.18 per share has been proposed.

During the first half of 2026, the group obtained 30 IND approvals, launched seven key products commercially, and initiated 18 additional pivotal Phase III clinical studies. The company also published 14 research findings in the period, including five oral presentations that garnered strong international recognition and widespread industry attention.

Currently, CSPC PHARMA holds a pipeline of over 200 innovative drugs and formulations in development, comprising more than 90 large molecules, over 60 small molecules, and more than 50 novel formulations—many of which boast significant market potential and demonstrate markedly superior efficacy and safety profiles compared to existing therapies.